Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Debt (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Debt over the past 15 years, most recently at $121.2 million for Q2 2025.

  • Quarterly results put Non-Current Debt at $121.2 million for Q2 2025, up 20.21% from a year ago — trailing twelve months through May 2025 was $121.2 million (up 20.21% YoY), and the annual figure for FY2025 was $121.2 million, up 20.21%.
  • Non-Current Debt for Q2 2025 was $121.2 million at Lifecore Biomedical, Inc. \De\, up from $115.7 million in the prior quarter.
  • Over the last five years, Non-Current Debt for LFCR hit a ceiling of $164.9 million in Q2 2021 and a floor of $8.5 million in Q4 2024.
  • Median Non-Current Debt over the past 5 years was $96.3 million (2024), compared with a mean of $82.6 million.
  • Biggest five-year swings in Non-Current Debt: tumbled 79.9% in 2023 and later soared 502.1% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Non-Current Debt stood at $124.2 million in 2021, then crashed by 35.91% to $79.6 million in 2022, then crashed by 78.8% to $16.9 million in 2023, then tumbled by 49.64% to $8.5 million in 2024, then surged by 1325.86% to $121.2 million in 2025.
  • The last three reported values for Non-Current Debt were $121.2 million (Q2 2025), $115.7 million (Q1 2025), and $8.5 million (Q4 2024) per Business Quant data.